What Is Lipegfilgrastim? Definition and What Research Reports

Definition

Lipegfilgrastim is a long-acting, glycoPEGylated recombinant form of human granulocyte colony-stimulating factor (G-CSF) that has been studied as a supportive-care agent in oncology. Published reviews describe it as a G-CSF product developed for the prophylaxis and treatment of chemotherapy-induced neutropenia, the drop in neutrophil counts that can follow cytotoxic chemotherapy (PMID 25409861, PMID 26858523). In the literature, the name refers to a specific engineered molecule rather than to a class: it is filgrastim — recombinant methionyl human G-CSF — modified by the covalent attachment of a polyethylene glycol chain through a carbohydrate (glyco) linker, a design that reviews discuss in the context of extending the circulating half-life of the parent protein (PMID 25878498). This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medical care or treatment.

What Class of Molecule Is It?

Lipegfilgrastim belongs to the recombinant protein therapeutics, specifically the haematopoietic growth factors. G-CSF is an endogenous cytokine that acts on the G-CSF receptor on myeloid progenitor cells and mature neutrophils, driving neutrophil production, release from the bone marrow and functional activation. Because it is a full-length recombinant protein carrying a glycan-linked PEG moiety, it sits at the larger end of the "peptide" spectrum: it is not a short synthetic peptide made by solid-phase synthesis, and it is not an analogue of a small signalling peptide. Reviews classify it among the long-acting G-CSFs alongside pegfilgrastim, in contrast to the short-acting parent molecule filgrastim (PMID 26858523, PMID 28614980).

Where the molecule comes from

The protein backbone is produced recombinantly rather than extracted from human tissue, and the PEG chain is added by chemical–enzymatic modification during manufacture. Nanomedicine and clinical-pharmacology reviews have framed this glyco-PEGylation approach as the defining engineering feature that distinguishes lipegfilgrastim from earlier G-CSF products (PMID 25878498, PMID 25409861). Regulatory context matters for how the term appears in the literature: lipegfilgrastim is a licensed biological medicine in the European Union, so most publications describe supervised clinical or post-marketing use, and the drug utilisation literature reflects prescribing in routine European oncology practice (PMID 36044089).

How the Term Is Used in Research Writing

In published work, "lipegfilgrastim" is used in three broad ways:

• As a named investigational or comparator product in randomized trials and indirect comparisons against placebo, pegfilgrastim or filgrastim (PMID 28614980).
• As a pharmacology case study in glyco-PEGylation and protein half-life extension, where its pharmacokinetic and pharmacodynamic behaviour is characterised in healthy volunteers (PMID 25251999).
• As an exposure variable in non-interventional, pooled and real-world effectiveness or safety analyses across tumour types (PMID 34123810, PMID 33716632).

Readers scanning peptide literature should note that lipegfilgrastim is a prescription biologic studied in cancer patients receiving chemotherapy, not a research chemical marketed for general performance or wellness contexts. It does not appear in the literature as a research-use-only peptide.

What the Published Literature Reports

Pharmacokinetics and pharmacodynamics

Two randomized studies in healthy volunteers examined body-weight-adjusted dosing alongside a 6 mg fixed dose, and the researchers characterised the pharmacokinetics and pharmacodynamics of each approach as part of dose selection for the clinical programme (PMID 25251999). Narrative reviews summarised the resulting profile as consistent with a long-acting G-CSF whose clearance is influenced by neutrophil-mediated mechanisms (PMID 25409861, PMID 25878498).

Controlled and comparative evidence

A post hoc analysis of patients with non-small cell lung cancer receiving chemotherapy compared lipegfilgrastim with placebo and reported on efficacy and safety separately in elderly and younger subgroups (PMID 27501966). A meta-analysis with indirect treatment comparison pooled trial data to assess lipegfilgrastim against pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events (PMID 28614980).

Non-interventional and real-world reports

The NADIR study examined prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (PMID 30347466), while the Protroca non-interventional study looked at prophylactic use in non-selected breast cancer patients (PMID 33716632). A further routine-practice analysis assessed the effectiveness of febrile neutropenia prophylaxis with lipegfilgrastim outside the trial setting (PMID 28438855), and a pooled analysis focused on effectiveness and safety in patients with urological malignancies in the real-world setting (PMID 34123810). A multinational drug utilisation study described how the product was actually prescribed across European settings (PMID 36044089).

Safety and Tolerability: What Studies Report

Safety reporting for lipegfilgrastim is distributed across the same body of work. The post hoc non-small cell lung cancer analysis reported safety outcomes alongside efficacy in elderly and younger patients receiving chemotherapy (PMID 27501966), and the pooled real-world analysis in urological malignancies also addressed safety in routine practice (PMID 34123810). A published report in an oncology pharmacy practice journal described hyperleukocytosis — an excessive rise in white blood cell count — as a possible occurrence with lipegfilgrastim (PMID 35200056). Reviews of the drug's clinical pharmacology likewise summarised tolerability within the broader G-CSF class, where bone pain is a characteristic class-level complaint discussed by researchers (PMID 25409861, PMID 26858523).

Related Terms

• Filgrastim — the unmodified short-acting recombinant G-CSF that forms the protein backbone, used as a comparator in the indirect comparison literature (PMID 28614980).
• Pegfilgrastim — a separate long-acting PEGylated G-CSF, also a comparator in the same meta-analysis (PMID 28614980).
• Chemotherapy-induced neutropenia / febrile neutropenia — the outcomes around which nearly all lipegfilgrastim research is organised (PMID 28438855).
• Glyco-PEGylation — the half-life-extension strategy reviews use to distinguish the molecule pharmacologically (PMID 25878498).

Limitations of the Evidence

Much of the post-approval literature is non-interventional, meaning treatment was not randomised and comparison groups were often absent, as in the breast cancer and routine-practice reports (PMID 33716632, PMID 28438855). Indirect treatment comparisons rely on assumptions about trial similarity rather than head-to-head randomisation (PMID 28614980). Reported findings apply to the supervised oncology populations studied and are not generalisable beyond them. Again, this entry is educational only and is not medical advice; questions about neutropenia, chemotherapy support or any prescription biologic belong with a licensed physician.

References

• Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia (Expert Review of Clinical Pharmacology, 2015)
• Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients (Biologics: Targets & Therapy, 2016)
• Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia (International Journal of Nanomedicine, 2015)
• Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers (Current Medical Research and Opinion, 2014)
• Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events (Journal of Oncology Pharmacy Practice, 2018)
• Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients (Supportive Care in Cancer, 2016)
• Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study) (European Journal of Haematology, 2019)
• Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients (Breast Care, 2021)
• The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice (In Vivo, 2017)
• Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting (Frontiers in Oncology, 2021)
• A multinational, drug utilization study of lipegfilgrastim use in real-world setting in Europe (Supportive Care in Cancer, 2022)
• Lipegfilgrastim may cause hyperleukocytosis (Journal of Oncology Pharmacy Practice, 2022)